Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
As of close of business last night, Regenxbio Inc’s stock clocked out at $9.81, up 2.94% from its previous closing price of $9.53. In other words, the price has increased by $2.94 from its previous closing price. On the day, 0.89 million shares were traded.
Ratios:
To gain a deeper understanding of RGNX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.93 and its Current Ratio is at 2.93. In the meantime, Its Debt-to-Equity ratio is 0.49 whereas as Long-Term Debt/Eq ratio is at 0.30.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on February 11, 2025, Downgraded its rating to Neutral and sets its target price to $14 from $38 previously.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 12 ’25 when Mills Kenneth T. sold 20,602 shares for $7.91 per share. The transaction valued at 163,046 led to the insider holds 475,103 shares of the business.
KENNETH MILLS bought 20,602 shares of RGNX for $154,927 on May 12 ’25. On Dec 30 ’24, another insider, VITTAL VASISTA, who serves as the Officer of the company, bought 20,041 shares for $7.41 each.
Stock Price History:
Over the past 52 weeks, RGNX has reached a high of $15.36, while it has fallen to a 52-week low of $5.03. The 50-Day Moving Average of the stock is 19.24%, while the 200-Day Moving Average is calculated to be 10.89%.
Shares Statistics:
A total of 50.12M shares are outstanding, with a floating share count of 45.45M. Insiders hold about 9.39% of the company’s shares, while institutions hold 87.56% stake in the company.
